Cryptosporidiosis is an infectious disease caused by the Cryptosporidium parasite, primarily affecting the gastrointestinal tract of both humans and animals. Transmission occurs via fecal-oral route, mainly through ingestion of water or food contaminated with oocysts, the parasite’s infectious form. Immunocompromised individuals are particularly susceptible to severe and prolonged symptoms. Current treatment strategies involve supportive measures and antiparasitic medications such as nitazoxanide and paromomycin, although patients with predisposing factors have an elevated risk of recurrence. There is currently no evidence supporting the use of paromomycin via nasogastric tube. Therefore, we present our experience with the use of an extemporaneous paromomycin solution and its clinical impact.
PonticelliCPasseriniP.Gastrointestinal complications in renal transplantrecipients. Transp Int. 2005;18(6):643-650.
4.
KhalilIATroegerCRaoPC, et al. Morbidity,mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in childrenyoungerthan 5 years: a meta-analyses study. Lancet Glob Health. 2018;6(7):e758-e768.
5.
WhiteACChappellCLHayatCSKimballKTFlaniganTPGoodgameRW.Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis. 1994;170(2):419-424.
6.
HashmeyRSmithNHCronSGravissEAChappellCLWhiteAC.Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine. 1997;76:118-139.
7.
ChieffiPPSensYAPaschoalottiMAMiorinLASilvaHGJaburP.Infection by Cryptosporidium parvum in renal patients submitted to renal transplant or hemodialysis. Rev Soc Bras Med Trop. 1998;31(4):333-337.
8.
Martínez NúñezMEHernández MuniesaB.Prevención del síndrome de realimentación [Prevention of the refeeding syndrome]. Nutr Hosp. 2010;25(6):1045-1048.
9.
BlanshardCShansonDCGazzardBG.Pilotstudies of azithromycin, letrazuril and paromomycin in thetreatment of cryptosporidiosis. Int J STD AIDS. 1997;8:124.
KhanWKumarN.Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development. Drug Test Anal. 2011;3(6):363-372.
15.
Diaz-ToméVAlonsoJMFerroI. Elaboración de otros colirios antiinfecciosos. In: AFFerreiro, ed. Formulación Magistral Oftálmica Antiinfecciosa. SEFH; 2019:165-166.
16.
OlsonLLPickJEllisWYLimP.A chemicalassessment and HPLC assayvalidation of bulkparomomycin sulfate. J Pharm Biomed Anal. 1997;15(6):783-793.
LinJZhouDSteitzTAPolikanovYSGagnonMG.Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design. Ann Rev Biochem. 2018;87(1):451-478.
19.
HewittRGYiannoutsosCTHiggsES, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS clinical trial group. Clin Infect Dis. 2000;31(4):1084-1092.
20.
HussienSMAbdellaOHAbu-HashimAH, et al. Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children. J Egypt Soc Parasitol. 2013;43(2):463-470.
21.
Peña PedrosaJASantiago PérezAArenaza PeñaAE, et al. Guía de Administración de Medicamentos Por Sonda de Alimentación Enteral. Hospital Clínico San Carlos. Madrid; 2012.
22.
Tejedor TejadaEGonzalez SuárezSLizondo LópezTLópez-CabezasCSoy MunerD. Alternatives for the administration of oral antineoplastics in patients with swallowing difficulties. J Chemother. 2024:1-14.
23.
De Andrés MoreraSAlvarez CriadoJMoreno PalominaM, et al. Guía para la administración de medicamentos a pacientes con problemas de deglución; 2021.
